Cyclooxygenase-independent actions of cyclooxygenase inhibitors

IRMGARD TEGEDER, JOSEF PFEILSCHIFTER, AND GERD GEISSLINGER[1]
Pharmazentrum Frankfurt, Klinikum der Johann Wolfgang Goethe-Universität,
Frankfurt, 60590 Frankfurt am Main, Germany

ABSTRACT   Several studies have demonstrated unequivocally that certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as sodium salicylate, sulindac, ibuprofen, and flurbiprofen cause anti-inflammatory and antiproliferative effects independent of cyclooxygenase activity and prostaglandin synthesis inhibition. These effects are mediated through inhibition of certain transcription factors such as NF-κB and AP-1. The respective NSAIDs might interfere directly with the transcription factors, but their effects are probably mediated predominantly through alterations of the activity of cellular kinases such as IKKβ, Erk, p38 MAPK, or Cdks. These effects apparently are not shared by all NSAIDs, since indomethacin failed to inhibit NF-κB and AP-1 activation as well as Erk and Cdk activity. In contrast, indomethacin was able to activate PPARγ, which was not affected by sodium salicylate or aspirin. The differences in cyclooxygenase-independent mechanisms may have consequences for the specific use of these drugs in individual patients because additional effects may either enhance the efficacy or reduce the toxicity of the respective compounds.—Tegeder, I., Pfeilschifter, J., Geisslinger, G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors *FASEB J*. 15, 2057–2072 (2001)

Key Words: aspirin · NSAIDs · apoptosis · metalloproteinase

ASPIRIN-LIKE DRUGS, now referred to as nonsteroidal anti-inflammatory drugs (NSAIDs), have been used to treat arthritis since 1899, when the analgesic and anti-inflammatory effects of aspirin were first recognized. Despite their potential gastrointestinal and renal toxicities, they are among the most widely used therapeutic classes of compounds primarily because they are generally effective for the relief of pain and inflammation. More recently, aspirin and some other NSAIDs have received attention because of their protective effects against colon cancer (1–3) and cardiovascular disease (4–7). Recently, celecoxib, a selective COX-2 inhibitor, was approved by the FDA for the prevention of colon cancer in patients with familial polyposis coli, which is a hereditary precancerous disease due to a loss of the adenomatous polyposis coli (APC) tumor suppressor gene. NSAIDs may help to prevent or delay the onset of Alzheimer's disease (AD) (8, 9). It is generally accepted that the anti-inflammatory and analgesic efficacy of NSAIDs arises mainly from inhibition of the enzymatic activity of cyclooxygenases (COX), which convert arachidonic acid to prostaglandins (PGs) (10). Two COX isoforms have been described. COX-1 is constitutively expressed in almost all tissues and has characteristics of a housekeeping enzyme whose activity depends solely on the availability of its substrate. COX-1 supplies tissues with prostaglandins required to maintain physiological organ function, such as cytoprotection of the gastric mucosa and regulation of renal blood flow. Conversely, COX-2 behaves as an immediate early gene (11) and is subject to rapid regulation at the transcriptional level. COX-2 is up-regulated in peripheral tissues and the spinal cord in response to tissue injury and is thought to produce excessive amounts of prostaglandins that serve to sensitize nociceptors and stimulate the release of other inflammatory mediators. Prostaglandins also contribute to tumor growth by inhibiting apoptosis (12) and inducing the formation of new blood vessels that sustain tumor cell viability and growth (13, 14). COX inhibition may thus explain part of the antitumor activity of certain NSAIDs. However, some lines of evidence suggest that NSAIDs also modulate cyclooxygenase-independent signal transduction pathways, which may be involved in both the anti-inflammatory and antitumor activity of these drugs (15–17).

For example, doses of aspirin necessary to treat chronic inflammatory diseases are much higher than those required to inhibit PG synthesis. Whereas aspirin inhibits COX activity by acetylating the enzyme salicylic acid, which lacks the acetyl group and is ineffective as a COX inhibitor at therapeutic doses, it is nevertheless able to reduce inflammation (18–20). We have recently shown that R-flurbiprofen, which was generally considered the noncyclooxygenase-inhibiting 'inactive' counterpart of S-flurbiprofen, reduces inflammation (21), hyperalgesia (22), and nociception-induced release of PGE_2 from the spinal cord (23). In addition, R-flurbiprofen was reported to reduce tumor formation and progression in $APC^{Min/+}$ and TRAMP mice, which are in vivo models for colon and prostate cancer, respec-

tively (24, 25). It is important to note that mechanisms that have been suggested to contribute to the antitumor activity of NSAIDs such as inhibition of cell cycle progression (17, 26), induction of apoptosis (27–29), and inhibition of angiogenesis (30, 31) have been observed only at high concentrations of the respective NSAIDs, which are 100- to 1000-fold higher than those needed to inhibit prostaglandin synthesis (**Table 1**). Furthermore, NSAIDs inhibit tumor formation and growth in COX-deficient cell lines (16, 32). These data leave little doubt that cyclooxygenase-independent mechanisms account for part of the effects of certain NSAIDs, at least at high doses.

CYCLOOXYGENASE-INDEPENDENT MECHANISMS OF NONSELECTIVE NSAIDs

Nuclear factor kappa B (NF-κB)

Cyclooxygenase-independent anti-inflammatory effects

Since Kopp and Ghosh (33) first reported that sodium salicylate and acetylsalicylic acid (aspirin) inhibit the activation of NF-κB, much interest has focused on this transcription factor as a potential target for certain NSAIDs. The vertebrate Rel/NF-κB transcription factor family includes five cellular proteins: c-Rel, RelA (p65), RelB, p50, and p52. As homodimers and heterodimers, Rel/NF-κB proteins bind to DNA target sites, collectively called κB sites, and directly regulate gene transcription. A single cell can have an array of diverse dimeric complexes, the most common of which is called NF-κB and consists of a p50/RelA heterodimer. Since NF-κB regulates the expression of proinflammatory enzymes, cytokines, chemokines, immunoreceptors, and cell adhesion molecules, it has often been termed a "central mediator of the immune response" (34, 35). Because of this key role, it was suggested that the inhibition of NF-κB observed might contribute considerably to the anti-inflammatory effects of salicylates (33, 36). However, this was not confirmed using the murine air pouch as a model of inflammation. In mice deficient in p105 (the precursor of the p50 component of NF-κB), aspirin and sodium salicylate retained their anti-inflammatory efficacy (37). Inhibition of inflammation was also independent of prostaglandin synthesis but was completely reversed by injection of an adenosine A2 receptor antagonist into the air pouch (37), suggesting that modulation of adenosine release or action was somehow involved. Indeed, aspirin and sodium salicylate caused cells to release adenosine into the inflammatory exudate, which was associated with a reduction of leukocyte accumulation (37).

In contrast to salicylates, the anti-inflammatory effects of dexamethasone, which is known to inhibit the activation of NF-κB (38–40), were completely abolished in p105 knockout mice (37). Thus, effects of salicylates and dexamethasone apparently were mediated through different mechanisms in this model.

However, it cannot be excluded that NF-κB is a major target of NSAIDs in other models. Recently, we found that NF-κB was inhibited by R- and somewhat less by S-flurbiprofen, which was associated with a decrease in NF-κB-dependent gene transcription (21). Although R-flurbiprofen does not inhibit cyclooxygenase activity and is not epimerized to S-flurbiprofen in rats, it reduced zymosan-induced paw inflammation more potently than S-flurbiprofen and was almost as effective as dexamethasone, suggesting that NF-κB may be a primary target of R-flurbiprofen.

Inhibition of immune cell maturation and cytokine production

The functions of NF-κB in inflammation also include the regulation of immune cell differentiation and survival. The maturation of dendritic cells in particular depends on the activation of NF-κB (41). Immature dendritic cells differentiate on exposure to inflammatory signals such as cytokines. Matured cells are then able to initiate immune responses and are thought to contribute to the pathogenesis of autoimmune diseases by inappropriate presentation of self-antigens. When immature human myeloid dendritic cells were differentiated in vitro in the presence of aspirin or sodium salicylate, they were unable to stimulate T cell proliferation (42). This was associated with a change of cell surface marker proteins. Levels of CD83 and interleukin 12 (IL-12), both markers of mature dendritic cells, were markedly reduced, indicating that salicylates inhibited the differentiation process. The effect was mediated through inhibition of NF-κB and was independent of prostaglandin synthesis (42). The inhibitory effect occurred at concentrations (IC$_{50}$: 2.5 mM) similar to those found in plasma after administration of anti-inflammatory doses (1–2 mM). Thus, inhibition of immune cell differentiation may contribute to the anti-inflammatory effects of salicylates. Dendritic cell maturation was also inhibited by dexamethasone (43) whereas other NSAIDs, including ketoprofen, indomethacin, and NS398, a COX-2-selective agent, had no effect (42), which suggests that these NSAIDs did not inhibit NF-κB activation up to the concentrations tested in that study (100, 200, and 900 μM, respectively).

Inhibition of NF-κB in immune cells also results in a decrease in cytokine production (44–46). Aspirin and sodium salicylate were recently found to inhibit the transcription of IL-4 in CD4+ human T lymphocytes independent of NF-κB inhibition and PG synthesis (47). The effect occurred at concentrations of 1 mM and was caused by a reduced binding of a Ca^{2+}-inducible complex to an IL-4 promotor element upstream and not overlapping with the NF-κB binding site (47). Analysis of the sequence suggested that an Ets family member and/or a zinc binding protein might be involved in this complex (47). In contrast to salicylates, indomethacin and flurbiprofen had no effect (47). IL-4 is the prototypical cytokine of T helper 2 cells and plays a major role in the regulation of hematopoiesis and

TABLE 1. *Effect of different NSAIDs on cyclooxygenases, transcription factors, and diverse kinases[a]*

| | COX1-IC$_{50}$ (μM) | COX2-IC$_{50}$ (μM) | Transcription factors | | | | Kinases — MAP-kinase cascade | | | | | | | Cell cycle | | | | NAG-1 (mM) | Heat shock | | Nuclear receptors | |
			NF-κB (mM)	AP-1 (mM)	cMyc (mM)	STAT1 (mM)	IKK (mM)	Erk1/2 (mM)	p38 (mM)	JNK (mM)	p90RSK (mM)	Akt/PKB (mM)	p70-S6K (mM)	Cdks (mM)	Cyclins (mM)	p21/p27 (mM)	p53 (mM)		HSF-1 (mM)	Hsp70 (mM)	PPARγ (mM)	PPARδ (mM)
Acetylsalicylic acid (aspirin)	↓[b] (2.8)	↓[c] (26)	→ (2–10)	→ (2–10)	→ (5)		→ (2–5)	→ (20)	← (10)	↑→ (10, 2)	→ (1–3)			↓ (1–10)	← (1–10)	← (1–10)	← (1–10)	← (10)	← (3)	← (3)	↔ (–10)	↔ (–10)
Sodium salicylate	↔[c] (>100)	↔[c] (>100)	→ (5–20)	→ (2–20)	→ (5)	← (3–20)	→ (10)	→ (20)	← (20)	→↑ (20, 2)	→ (5–20)		→ (2–10)	↓ (1–10)	← (1–10)	← (1–10)	← (1–10)	← (5)	← (20)	← (20)	↔ (–20)	↔ (–20)
Sulindac silfide	↓[d] (0.15)	↓[d] (0.0008)	↓↑ (0.2–1)				→ (0.2)	→ (0.04–0.6)		→ (0.2)				→ (0.2)	→ (0.2)			(0.05)		← (0.2–0.6)		↓ (0.1–0.2)
Ibuprofen	→[b] (2.1)	↓[b] (1.6)	→ (0.1–1)				→ (0.1)	→ (2)			→ (1–2)							← (0.5)			← (0.1)	
S-flurbiprofen	→[b] (0.03)	↓[b] (0.9)	→ (0.1–1)	↔ (–1)			↔ (–1)															
R-flurbiprofen	↔[b] (>40)	↔[c] (>100)	→ (0.01–1)	→ (0.1–1)			↔ (–1)															
Ketoprofen	↓[b] (0.3)	↓[c] (0.6)	↔ (–1)																			
Indomethacin	↓[b] (0.2)	↓[c] (0.7)	↔ (–2)		← (0.4)			↔ (–0.25)	↔ (–0.25)	↔ (–0.25)				↔ (–0.25)	↔ (–0.25)	← (0.4)	← (0.4)	← (0.1)		↔ (–0.3)	← (0.1)	→ (0.2–0.4)
Celecoxib	↔[b] (>7)	↓[b] (0.9)	← (0.05)					→ (0.1)				↓ (0.05)										
NS398	↔[b] (>10)	↓[b] (0.1)	↔ (–9)											→ (0.1)	→ (0.1)	← (0.1)		↔ (–0.1)			↔ (–1)	

[a] (↓) Inhibition, down-regulation, or reduction of activity (concentration or concentration range at which the effect was observed); (↑) stimulation, induction, or increase of activity (concentration or concentration range at which the effect was observed); (↔) no change of expression or activity (concentration up to which the effect was assessed); (↑↓) both inhibition and activation have been reported. [b] IC$_{50}$ values were obtained with the whole blood assay, i.e., LPS-stimulated PGE$_2$ production in blood monocytes was used for COX-2 activity and TXB$_2$ release from clotting whole blood was used for COX-1 activity: ibuprofen (210); S- and R-flurbiprofen (23); indomethacin (23); celecoxib (212); NS398, modified whole blood assay (213); acetylsalicylic acid (214); sodium salicylate (215). [c] IC$_{50}$ values were obtained by determining PGE$_2$ production of IL-1β-stimulated synovial fibroblasts [ketoprofen (216), acetylsalicylic acid (217)] or IL-1β-treated A549 cells (sodium salicylate; 215). [d] IC$_{50}$ values for COX-1 were obtained by determination of PGE$_2$ production in undifferentiated U937 cells that express COX-1 exclusively (sulindac sulfide; 218). Note that IC$_{50}$s for COX-1 and COX-2 inhibition are given in μM and concentrations needed to produce other effects are given in mM. Abbreviations: COX, cyclooxygenase; NF-κB, nuclear factor kappa B; AP-1, activator protein 1; STAT, signal transducer and activator of transcription; IKK, I-kappa kinase; Erk, extracellular signal-regulated kinase; MAP-kinase, mitogen-activated protein kinase; JNK, Jun NH$_2$-terminal kinase; RSK, ribosomal S6 kinase; Akt/PKB, protein kinase B; p70-S6K, p70S6 kinase; Cdk, cyclin-dependent kinase; HSF, heat shock factor; Hsp, heat shock protein; PPAR, peroxisome proliferator-activated receptor.

immune responses (48). It is also involved in the pathogenesis of autoimmune diseases such as juvenile rheumatoid arthritis and Kawasaki syndrome, where the effectiveness of aspirin is well documented (49, 50). Thus, inhibition of IL-4 production may be an additional mechanism by which salicylates modulate immune function.

Decision between induction of apoptosis or cell survival

NF-κB is involved in the control of the transcription of many genes whose function extends beyond the immediate immune response. Similarly, several activators are not bacterial or viral pathogens. Therefore, rather than being a central mediator of immune responses, NF-κB probably represents a 'regulator of stress responses'. Hence, NF-κB also functions as a regulator of the apoptotic program either for induction of apoptosis or, more commonly, as its inhibitor. Whether NF-κB pro-

motes or inhibits apoptosis appears to depend on the cell type and the type of inducer (**Fig. 1**). In numerous human cancer cells, NF-κB is persistently active, which results from a constitutive activation of upstream signaling kinases or mutations that inactivate IκB subunits (51). The persistent activation of NF-κB renders these cells more resistant to chemo- or radiotherapy (52, 53) or other agents that induce apoptosis. The salicylate-induced inhibition of NF-κB translocation might reconstitute the sensitivity of these cancer cells to apoptosis inducing treatment (54) and thereby contribute to the antitumor activity of salicylates. NF-κB activity is also required for the oncogenic transformation by ras and raf (55, 56). Mutations of ras are found in ~50% of colon cancers and play an important role in the multistage process of carcinogenesis. Salicylates were found to inhibit the growth of v-ras transformed fibroblasts. This effect depended on the ability to inhibit NF-κB but was independent of prostaglandin synthesis (57). In rat


Figure 1. Activation or induction (→); inhibition (⊣); inhibited by NSAIDs (shaded oval); activated by NSAIDs (oval). Abbreviations: Akt/PKB, protein kinase B; APC adenomatous polyposis coli tumor suppressor gene; AP-1 activator protein 1; Cdk, cyclin-dependent kinase; CREB, cAMP response element binding protein; Erk, extracellular signal-regulated kinase; GSK3β, glycogen synthase kinase 3 beta; HSF, heat shock factor; Hsp, heat shock protein; IKK, I-kappa kinase; JNK, Jun NH$_2$-terminal kinase; MAPK, mitogen-activated kinase; MAPKAP, MAPK-activated protein kinase; MEK/MKK, mitogen-activated protein kinase kinase; MLK, mixed lineage kinase; MSK, mitogen- and stress-activated kinase; NIK, nuclear factor kappaB-inducing kinase; NF-κB, nuclear factor kappa B; PAK, p21-GTPase-activated kinase; PDK, phosphoinositol-dependent kinase; PI-3K, phosphatidylinositol-3-kinase; PKC, protein kinase C; PPAR, peroxisome proliferator-activated receptor; pRb, retinoblastoma protein; p70-S6K, p70S6 kinase; p90RSK, ribosomal S6 kinase; Tcf, T cell factor; Wnt (syn Wg), wingless

intestinal epithelial cells, ras-induced transformation led to an up-regulation of COX-2, which is constitutively expressed in > 80% of colorectal cancers and appears to contribute to colon carcinogenesis.

Conversely, NF-κB activation does not inhibit but promotes apoptotic cell death in a subset of neuronal cells including hippocampal neurons (58) and cerebellar granule cells (59). In these cells, salicylate and aspirin were shown to reduce glutamate-induced neurotoxicity, which was closely related to their ability to inhibit NF-κB activation (59). However, several lines of evidence suggest that NF-κB can also promote survival in neurons (60–62). For example, the β-amyloid peptide associated with AD appears to cause its neurodegenerative effects by down-regulation of NF-κB activity (63) probably through up-regulation of IκBα mRNA and protein expression (60). In contrast, exposure of astroglial cultures to β-amyloid peptide resulted in an activation of NF-κB and NF-κB-dependent gene transcription, including IL-1β and IL-6 (60, 64). Thus, alterations of NF-κB-directed gene expression may contribute to both the neurodegenerative and inflammatory response that occur in AD. The contradictory functions of NF-κB in cortical neurons and astroglial cells may partly explain the somewhat disappointing clinical results with NSAIDs in the treatment of AD (65–68). Unfortunately, some of these studies were performed with diclofenac (67) and indomethacin (68), which probably do not significantly inhibit NF-κB activation (see above).

The mechanisms by which NF-κB promotes cell survival are due in part to the up-regulation of antiapoptotic genes such as members of the bcl and IAP families (69–71). As a result, salicylate-induced cell death was associated with a down-regulation of MCL-1, a Bcl-2 family member (72). Less is known about target genes that may be involved in cells where NF-κB induces apoptosis. Since NF-κB activates the genes encoding Fas and Fas ligand (73–77), NF-κB activation might sensitize cells to agents that act through or cooperate with the Fas triggered death pathway.

Mechanisms involved in NF-κB inhibition

Inhibitor κ-B kinase (IKK) complex NF-κB transcription factors are regulated primarily by interaction with inhibitor IκB proteins. Thus, in most cells NF-κB exists in the cytoplasm in an inactive complex bound to IκB. Most agents that activate NF-κB do so through a common pathway, which is based on the phosphorylation-induced, proteasome-mediated proteolysis of IκB. The key regulatory step in this pathway involves activation of an IKK complex. Liberated NF-κB then translocates from the cytoplasm to the nucleus, where it binds to the κB-sites in the promoter region of target genes and regulates their transcription.

IKK inhibition through salicylates When cells were stimulated with lipopolysaccharides (LPS) in the presence of sodium salicylate or aspirin, the LPS-induced proteolysis of IκBα was abolished, which suggests that the observed NF-κB inhibition was mediated through inhibition of the phosphorylation and/or the subsequent proteasome cleavage of IκB (33). The effects of sodium salicylate and aspirin were observed at concentrations of 2–20 mM and 2–5 mM, respectively (33). In serum, salicylate concentrations of 1–2 mM are required for anti-inflammatory activity whereas concentrations of > 6 mM are toxic (47, 78). At concentrations in the range of 2–20 mM, salicylate also inhibited the activity of several other cellular kinases. Thus, the specificity of the observed NF-κB inhibition has been questioned (79). Nevertheless, subsequent studies have confirmed that both aspirin and sodium salicylate inhibit LPS- or cytokine-induced nuclear translocation of NF-κB by preventing IκBα phosphorylation and degradation (80). Furthermore, it was shown that aspirin could directly bind to and inhibit the kinase activity of IKKβ by reducing its ability to bind ATP (81). The competitive inhibition of the ATP binding to IKKβ provides a potential explanation for the ability of sodium salicylate to inhibit the activity of multiple kinases. However, this ability makes it more difficult to decipher which pathways are mediating the observed effects. The simultaneous inhibition of multiple signaling pathways may be important for the ability of salicylates to inhibit tumorigenic cell growth.

IKK activity with other NSAIDs Other NSAIDs including ibuprofen (1–3 mM; ref 82, 83), sulindac, sulindac sulfide (1 and 0.2 mM, respectively; ref 84), and R- and S-flurbiprofen (0.01–1 mM and 1 mM, respectively; ref 21) were also able to inhibit NF-κB activation. Indomethacin (0.025–0.25 mM; see ref 42, 84), ketoprofen, and ketorolac (up to 1 mM; ref (42), however, were inactive (Table 1). Among the NSAIDs found to inhibit NF-κB, R-flurbiprofen and sodium salicylate are the only substances that do not significantly inhibit cyclooxygenase activity and thus do not cause gastrointestinal toxicity. In contrast to salicylate (81), ibuprofen (83) and sulindac (84), which were shown to inhibit IKKβ, R-flurbiprofen affected neither the phosphorylation, degradation, nor expression of IκB, suggesting that the effects of R-flurbiprofen were independent of IKK activity and IκB gene transcription (21). Thus, flurbiprofen apparently acts through a different mechanism than sodium salicylate. It is possible that R-flurbiprofen directly interacts with NF-κB, as has been described for glucocorticoids (38), or targets proteins that facilitate the nuclear translocation of NF-κB such as heat shock protein 70 (hsp70) (85, 86), which has been shown to play an important role in the immunosuppressive activity of 15-deoxyspergualin (87, 88).

Inhibition of activator protein 1 (AP-1)

Inhibition of NF-κB through R-flurbiprofen resulted in a reduced expression of COX-2 and tumor necrosis factor α (TNF-α), whereas inducible nitric oxide synthase (iNOS) was unaffected (21). Aspirin and sodium salicylate also reduced the expression of adhesion molecules in endothelial cells (80, 89) and chemokines

such as monocyte chemoattractant protein 1 and interferon γ (IFN-γ) -inducible protein 10 in monocytes and macrophages (90–92).

The transcriptional response to NF-κB activation depends in part on the coactivation of other transcription factors, since more than one transcription factor generally is required to induce effective gene transcription. Thus, although NF-κB participates in the transcriptional regulation of > 150 target genes, salicylates and other NSAIDs will probably affect only some of them. The selection of target genes might depend on the cell type, type of stimulus, and additional effects on other transcription factors, such as AP-1. AP-1 is a protein complex consisting of products of the jun and fos oncogene families, which are activated in response to a number of stimulants including UV irradiation, growth factors, TNF-α, and IL-1. Some of the genes known to be regulated by AP-1 are involved in the immune and inflammatory responses or tumor formation and progression. Thus, AP-1 and NF-κB target genes partially overlap and most target genes are activated by both AP-1 and NF-κB. However, for some genes the effects may be contrary. For example, iNOS transcription is activated by NF-κB (93) but negatively regulated by AP-1 (94). These opposite effects may explain why R-flurbiprofen, which inhibited both NF-κB and AP-1, had no effect on iNOS expression (21).

Aspirin and sodium salicylate have been shown to inhibit epidermal growth factor and UV-induced AP-1 activation in mouse epidermal cells (95). Furthermore, R-flurbiprofen was shown to inhibit LPS-induced AP-1 activation in mouse macrophages (21). In Epstein-Barr virus-infected tumor cells, expression of the EBV-latent membrane protein, the primary oncoprotein of EBV, was associated with increased activity of both AP-1 and NF-κB, which resulted in up-regulation of metalloproteinase 9 (MMP-9) and enhanced tumor invasiveness (96). Aspirin and sodium salicylate were able to reduce MMP-9 levels and tumor invasion through concomitant inhibition of NF-κB and AP-1 (97). Metalloproteinases also play an important role in the degradation of cartilage and bone in chronic arthritis (98, 99). High NF-κB and AP-1 DNA binding activity was found in the synovium of patients with rheumatoid arthritis and osteoarthritis (100), which resulted in an up-regulation of metalloproteinases (100). A major metabolite of aceclofenac was recently shown to inhibit the production of pro-MMP-1, pro-stromelysin, and pro-MMP-2 in rheumatoid synovial cells (101). These effects may contribute considerably to the therapeutic efficacy of the respective NSAIDs.

Alterations of the MAP kinase cascade

It is not known whether salicylates or R-flurbiprofen directly inhibit AP-1 or influence other upstream targets. AP-1 is a downstream target of MAP kinase family members including extracellular signal regulated kinases (Erk-1 and -2; p42/p44 MAPK), Jun kinases (JNKs), and p38 MAPK, which are believed to be activated in response to stress signals. Aspirin and sodium salicylate were shown to inhibit UV-induced AP-1 activity in mouse epidermal cells through blocking the activity of Erk-1 and -2 (102). Other studies have confirmed that activation of Erk-1 and -2 can be blocked by sodium salicylate and aspirin under certain circumstances (103, 104). Effective concentrations were in the range of 1–5 mM. It was recently shown that inhibition of angiogenesis by COX-2-selective and unselective NSAIDs was mediated through direct effects on endothelial cells involving inhibition of Erk2 activity and interference with its nuclear translocation (31). In contrast to Erk-1 and -2, p38 MAPK was reported to be activated by sodium salicylate in human fibroblasts (105) and was associated with induction of apoptosis. Since activation of p38 leads to a down-regulation of NF-κB activity in these cells (105), the apoptosis may have been mediated in part through inhibition of NF-κB. The same authors found that salicylate inhibited the TNF-α-induced activation of c-Jun NH$_2$-terminal kinase (JNK) in human fibroblasts (106). On the other hand, in HT-29 colon cancer and COS-1 cells, salicylate treatment resulted in activation of JNK (107). The contradictory results suggest that the effects of salicylate on MAPK family members may depend on the cellular context and may result from unspecific effects on kinase activity.

Inhibition of ribosomal S6 kinase

Another kinase shown to be inhibited by sodium salicylate is the ribosomal S6 kinase 2 (p90RSK2) (108); aspirin (1–3 mM) and ibuprofen (1–2 mM) had similar effects. This kinase plays a critical role as effector of the Ras-mitogen-activated protein kinase pathway and as regulator of immediate early gene transcription. Since p90RSK2 is phosphorylated and activated by Erk-1 and Erk-2, these MAPK family members may have been the primary targets of salicylates. Nevertheless, sodium salicylate inhibited p90RSK2 activity and thereby suppressed the phosphorylation and activation of the p90RSK2 substrates, cAMP response element binding protein (CREB) and IκBα. This resulted in an inhibition of CREB and NF-κB-dependent gene transcription. Effective concentrations of salicylate were in the range of 5–20 mM.

Activation of signal transducer and activator of transcription (STAT1)

In contrast to the inhibitory activity of salicylates on NF-κB and AP-1, salicylates were recently found to enhance the IFN-γ-induced activation of STAT1 (signal transducer and activator of transcription) in mouse macrophages (RAW 264.7). Salicylates alone did not enhance the activity of this transcription factor, but prolonged its tyrosine phosphorylation and enhanced its nuclear translocation and DNA binding activity after IFN-γ treatment of the cells (109). STAT1 is phosphor-

ylated by Janus kinases after ligand binding to cytokine receptors. It has multiple transcriptional functions. Upon activation, it drives the expression of many genes such as p21^{waf1} (110), intercellular adhesion molecule-1 (111), or RANTES (112) but also suppresses the transcription of others such as collagenase 3 (113). These opposing characteristics apply to its role in facilitating the cross-talk between signal transduction pathways, as it participates in both synergistic activation and inhibition of gene expression. Using targeted gene disruptions in mice, it was shown that STAT1 mediates growth inhibitory signals and contributes to the host's rejection of tumors (114).

Regulation of the expression of a transforming growth factor β (TGF-β) family member

Another protein that might be involved in the antitumoral effects of NSAIDs was recently identified in HCT-116 colon cancer cells (115). The gene, designated 'NSAID-activated gene' (NAG-1) has an identical sequence with a recently described novel member of the TGF-β superfamily. In these studies, the protein was designated 'macrophage inhibitory cytokine' (116) and 'placental transforming growth factor β' (PTGF-β) (117). NAG-1 possesses proapoptotic and antitumorigenic activity. Incubation of HCT-116 cells with different NSAIDs, including sulindac sulfide, indomethacin, diclofenac, aspirin, and others, increased the expression of NAG-1 and initiated apoptosis, sulindac sulfide being the most potent NSAID tested (115). In antisense NAG-1 cells, NSAID-stimulated apoptosis was attenuated, suggesting that the proapoptotic effects of NSAIDs were mediated at least in part through NAG-1 up-regulation (115). Further studies demonstrated that NAG-1 (called PTGF-β in these studies) was regulated by the p53 tumor suppressor gene (118, 119), suggesting that NAG-1 induction by NSAIDs might depend on wild-type p53. Since NAG-1 expression also resulted in growth arrest and apoptosis in MCF-7 breast cancer cells (118), the NAG-1-mediated effects of NSAIDs are probably not restricted to cells of colonic origin.

Inhibition of cell cycle progression

Inhibition of p70S6 kinase

Salicylate was recently shown to inhibit the activation of p70S6 kinase at concentrations of 2–10 mM, which was associated with a down-regulation of c-*myc*, cyclin D1, cyclin A, and proliferating cell nuclear antigen (120). These target genes are known to play an important role in cell proliferation, and their down-regulation might contribute to salicylate-induced growth arrest. p70S6 kinase is a mitogen-activated kinase that is important for protein synthesis and G$_1$ cell cycle progression, and has been identified as a target of the immunosuppressant drug rapamycin (121). Inhibition of p70S6 kinase through sodium salicylate was associated with dephosphorylation on Thr-389, the major rapamycin-sensitive

site (120). A rapamycin-resistant mutant of p70S6 kinase was also resistant to salicylate-induced dephosphorylation (120). Rapamycin inhibits cell cycle transition from G$_1$ to S, mediated partly through a reduction of cyclin D1 mRNA and protein stability (121). Likewise, salicylate inhibited the progression from G$_1$ to S and reduced cyclin D1 levels (120). The latter effect was also observed in human pancreatic cancer cells (122).

Expression and activity of cyclins and cyclin-dependent kinases

Progression through the various phases of the cell cycle is regulated mainly by cyclins and cyclin-dependent kinases (Cdks) (123). The Cdks associate with cyclins before they are activated in discrete phases of the cell cycle. Cdks that participate in regulating cell cycle progression include *1)* Cdk4 (124) and Cdk6 (125), which control the progression through G$_1$ together with D-type cyclins; *2)* Cdk2, which regulates the G$_1$/S transition in association with cyclin E (126–129); and *3)* Cdc-2, which in concert with type A and B cyclins controls the G$_2$/M phase transition (130–133). The function of cyclins is controlled primarily by changes in cyclin levels whereas Cdks are regulated through phosphorylation. The activity of the Cdk/cyclin complex is further negatively regulated by a number of Cdk inhibitors, including p21 (waf1) and p27 (kip1). Cdks hyperphosphorylate the retinoblastoma protein (pRb). pRb is present in quiescent cells in a hypophosphorylated state and sequesters E2F transcription factors (134). Phosphorylation of pRb at multiple sites releases E2Fs. These in turn activate the transcription of genes required for the progression of the cell cycle such as cdc2 and cyclin A (135). Recently, sodium salicylate (5–10 mM) was shown to inhibit the proliferation of vascular smooth muscle cells (SMCs) through up-regulation of the Cdk inhibitors p27^{kip1} and p21^{waf1}. This was associated with a decrease in Cdk2 and to a lesser extent in Cdk6 activity, thus preventing hyperphosphorylation of pRb and cell cycle progression. Cyclin protein levels were unchanged (136). p21^{waf1} is a major target gene of the tumor suppressor p53, which is activated and up-regulated upon cellular stress, particularly DNA damage and hypoxia. In parallel to p21^{waf1}, salicylate treatment of SMCs caused an up-regulation of p53 (136), suggesting that the observed effects might represent a stress response induced by high salicylate concentrations. Salicylate treatment also resulted in a modest inhibition of NF-κB activity (136). Although it has been shown that NF-κB activity is essential for SMC proliferation (137), its modest inhibition could not explain the profound inhibition of SMC proliferation in that study (136). Neither Cdk nor NF-κB inhibition was observed with indomethacin (136). Similar to salicylates, however, sulindac (1.2 mM) and sulindac sulfide (0.2 mM) reduced the proliferation rate of HT-29 colon carcinoma cells and caused them to accumulate in the G$_0$/G$_1$ phase (17). This was associated with reduced expression and reduced catalytic

activity of cyclin-dependent kinases (Cdc2, Cdk2, and Cdk4) (17).

Inhibition of the heat shock response

Apart from the effects on kinase activity, sodium salicylate has the property of partially inducing the human heat shock response (138, 139). This effect is probably mediated through activation of the heat shock transcription factor 1 (HSF1) from a latent cytoplasmic form to a nuclear, DNA binding state (139, 140). HSF1 can function as both an activator of heat shock genes and a repressor of cytokine genes. Treatment of LPS-stimulated monocytes with sodium salicylate resulted in an inhibition of cytokine gene expression similar to that observed after heat shock or overexpression of HSF1 (140). Similar effects were obtained with aspirin, sulindac, ibuprofen, and piroxicam, which also induced HSP70 mRNA expression (140). Thus, exposure to certain NSAIDs may lead to a switch in gene expression, with suppression of cytokine and induction of stress genes (141). HSF1 appears to play a regulatory role in these effects. Since p90RSK2 may function as a repressor of HSF1 (142), the observed inhibition of RSK2 through sodium salicylate (see above) might be involved in the salicylate-induced activation of HSF1.

Modulation of the activity of nuclear receptor family members

Activation of peroxisome proliferator-activated receptor γ (PPARγ)

The multitude of effects observed with sodium salicylate and aspirin argue in favor of the hypothesis that actions of salicylates at high concentrations are mediated through effects on several cellular kinases (79). Since the interest has focused on salicylates and, more recently, COX-2-selective agents, it is not clear whether the effects observed with salicylates are shared with the majority of other NSAIDs. The results obtained with indomethacin, however, which inhibits neither NF-κB (84, 143, 144), AP-1 (95, 145), p42/p44 MAPK (103), nor cell cycle regulatory proteins (136), suggest that there are substance specific differences.

This is further supported by the finding that indomethacin, but not sodium salicylate binds to and activates PPARγ, a member of a superfamily of nuclear hormone receptors that function as ligand-dependent transcription factors (146). Three distinct PPAR isoforms—PPARα, δ, and γ—have been isolated and characterized (147). PPARs bind to sequence-specific DNA response elements as a heterodimer with the retinoic acid receptor (148). PPARγ is highly expressed in adipose tissue and plays an important role in regulating genes involved in lipid utilization and storage, adipocyte differentiation, and insulin action. The antidiabetic thiazolidinediones such as troglitazone are high-affinity ligands of PPARγ (K_d 40 nM; ref 149). They enhance insulin sensitivity and promote preadi-

pocyte differentiation in adipose tissue. Although the affinity of indomethacin to PPARγ is relatively low (K_d 100 μM; ref 150) vs. that of troglitazone, indomethacin was able to induce the differentiation of mesenchymal stem cells to adipocytes in vitro (150). Because of this feature, indomethacin has been used widely to study the process of adipocyte differentiation (151–154). Some other NSAIDs, including ibuprofen, fenoprofen, and flufenamic acid, also bind and activate PPARγ as assessed in reporter gene assays, but are less potent than indomethacin (150).

Some arachidonic acid metabolites, especially prostaglandin D_2 metabolites such as 15-deoxy-PGJ_2, are natural high-affinity PPARγ ligands (K_d 2 μM) (155–157) that promote adipocyte differentiation in vitro (158). Prostaglandin D_2 metabolites have not yet been identified in adipose tissue, but are major products of arachidonic acid metabolism in macrophages (159) and mast cells (160) raising the possibility that they might serve as endogenous PPARγ ligands in these cells. PPARγ is expressed in monocytes (161), bone marrow precursors (162), splenocytes, and helper T cells (163) and was shown to be up-regulated in activated macrophages (161, 164). Activation of PPARγ in response to 15-deoxy-PGJ_2 and synthetic PPARγ ligands resulted in inhibition of cytokine production in macrophages (161, 165, 166) and T cells (163) and reduced T cell proliferation (163). This effect was mediated in part by antagonizing the activities of the transcription factors AP-1, STAT, and NF-κB (161, 167). Thus, 15-deoxy-PGJ_2 can be expected to provide anti-inflammatory effects. This is supported by a recent study showing that 15-deoxy-PGJ_2 induces apoptosis in synoviocytes and suppresses adjuvant-induced arthritis in rats (168). Furthermore, inhibition of 15-deoxy-PGJ_2 synthesis through COX inhibitors was associated with an exacerbation of inflammation in the late stage of carrageenan-induced pleurisy in rats (169), i.e., at a stage dominated by mononuclear cells. Since this effect occurred with both indomethacin and NS398 (COX-2 selective), the unfavorable effect is apparently shared by selective and unselective NSAIDs. Since indomethacin is only a weak PPARγ agonist, reduction of the endogenous PPARγ ligand 15-deoxy-PGJ_2 is probably not offset by its activity.

Besides its role in adipogenesis and inflammation, PPARγ is highly expressed in the normal large intestine and in breast, colon, and prostate cancer (170–172). PPARγ agonists such as troglitazone and 15-deoxy-PGJ_2 were able to induce differentiation and apoptosis in tumor cells (170–173), suggesting that PPARγ suppresses tumor cell proliferation. This is further supported by the finding that human colon cancer is associated with loss-of-function mutations of PPARγ (174). Indomethacin was shown to reduce the clonogenic activity of prostate cancer cells (172) and increase the antiproliferative effect of 5-fluorouracil in colon cancer cells (175).

Inhibition of peroxisome proliferator-activated receptor δ (PPARδ)

Unlike the PPARα and PPARγ receptors, little is known about the physiological functions of PPARδ. Recently, PPARδ was shown to play an important role in the female reproductive process (176). PPARδ was activated by prostacyclin (PGI$_2$), which is the major PG subtype at the implantation site where levels of PPARδ were significantly increased (176). In COX-2 knockout mice, which exhibit multiple reproductive failures (including implantation defects), the stable PGI$_2$ analog carbaprostacyclin (cPGI$_2$) and PPARδ agonists were able to reverse the implantation defect (176). Cicaprost, however, which can activate IP$_2$ receptors but does not activate PPARδ, did not reverse the deficiency, suggesting that the actions of PGI$_2$ were mediated through activation of PPARδ (176). Since PGI$_2$ synthesis is inhibited by selective and nonselective NSAIDs, PPARδ activity can be expected to be reduced.

Besides its role in reproduction, PPARδ has recently been identified as one of the downstream targets of β-catenin. The β-catenin protein plays a critical role in embryonic development and oncogenic processes through its effects on E-cadherin-mediated cell adhesion and as an effector of Wnt-dependent signal transduction. In the absence of Wnts, β-catenin is phosphorylated by glycogen synthase kinase 3 (GSK-3β), which triggers ubiquitination of β-catenin and degradation in proteasomes. Conversely, Wnt signaling leads to an inhibition of GSK-3β and stabilization of cytosolic β-catenin (177), which is then transferred into the nucleus where it binds to members of the Tcf (T cell factor)/Lef (lymphoid enhancing factor) transcription factor family. The β-catenin/Tcf complex up-regulates the expression of β-catenin/Tcf-dependent genes including c-*myc* (178), cyclin D1 (179), PPARδ (180), and gastrin (181). The phosphorylation and degradation of β-catenin occurs only when β-catenin is complexed with conductin/axin and the APC tumor suppressor gene, which acts as a cofactor (182). Several studies have suggested that a major function of APC is to down-regulate cytosolic levels of β-catenin (183–185), thus preventing the formation of β-catenin/Tcf complexes and transcription of β-catenin-dependent oncogenes. An inactivating mutation of the APC gene is an early event in the development of colon and other cancers. Moreover, inherited mutations of APC cause familial adenomatous polyposis, which is characterized by the development of hundreds of colorectal adenomas that result in colon cancer in all affected individuals. The pivotal role played by APC/β–catenin interaction is underscored by the observation that in tumors where the APC gene is not lost or mutated, mutations are frequently found in β-catenin (186, 187). Accordingly, restoration of APC function in colorectal cancer cells with defective APC results in growth suppression and apoptosis (188).

Recently, sulindac and etodolac were shown to increase the expression of APC mRNA in the colon of rats treated with the colon-specific carcinogen azoxymethane (189). The increase in APC mRNA expression was associated with a reduction of preneoplastic lesions (aberrant crypt foci) (189). Furthermore, aspirin (190) and indomethacin (191) were shown to decrease intracellular β-catenin levels, associated in the case of aspirin with a reduction of the rate of tumor formation in APC Min/+ mice (190). PPARδ was recently identified as one of the target genes of the APC/β-catenin-Tcf pathway (180) and its expression was shown to be up-regulated in colorectal carcinomas (192). As mentioned, PGI$_2$ can act as an activator of PPARδ (176, 192). Thus, NSAID-mediated inhibition of eicosanoid metabolism is likely to result in a repression of PPARδ activity. This theory was supported by the finding that sulindac sulfide inhibited carbaprostacyclin (cPGI$_2$)-stimulated DNA binding activity of the PPARδ/RXR heterodimer, which was associated with induction of apoptosis in colorectal cancer cells (180). A similar effect was observed with the sulindac sulfide-related compound sulindac sulfone, which is devoid of COX inhibitory activity (193), suggesting that inhibition of PPARδ was in part mediated by a direct, prostaglandin-independent effect (180). Directly or indirectly, the suppression of PPARδ activity associated with the promotion of apoptosis can compensate for APC or β-catenin mutations, which result in an increased expression of PPARδ and constitute an early step in colon carcinogenesis. Thus, inhibition of PPARδ activity may contribute to the chemopreventive activity of NSAIDs.

Induction of the orphan nuclear receptor NFGI-B (Nur77)

Indomethacin was recently found to induce another member of the steroid-thyroid hormone receptor family, nerve growth factor-inducible B (NGFI-B), also termed Nur77 or TR3 (194). NGFI-B is one of the immediate early genes originally identified by virtue of its rapid activation by nerve growth factor (NGF) in PC12 pheochromocytoma cells (195) and by serum in fibroblasts (196). NGFI-B is rapidly synthesized in response to a variety of growth factors, phorbol esters, and treatments resulting in calcium influx. The protein is modulated by phosphorylation; the extent of phosphorylation depends on the stimulus. NGFI-B binds as monomer to a relatively simple response element, which implies it has the potential to activate a wide array of target genes (197). In contrast to other nuclear receptor family members, which need their respective ligands to gain transcriptional competence, NGFI-B is constitutively active when expressed (197). The action of NGFI-B has been shown to be necessary for activation-induced cell death in T cells and thymocytes (198–200). In response to apoptotic stimuli, NGFI-B translocates from the nucleus to mitochondria to induce cytochrome *c* release and apoptosis (201). The induction of NGFI-B by indomethacin was associated with induction of apoptosis in HCT-15 colon cancer cells (194). Since these cells lack COX-2 expression,

NFGI-B induction appears to be independent of COX-2.

CYCLOOXYGENASE-INDEPENDENT ACTIONS OF COX-2-SELECTIVE DRUGS

Activation of NF-κB through celecoxib

In contrast to most other NSAIDs, celecoxib and rofecoxib are not acidic compounds. Apart from their COX-2 selectivity, they differ chemically from other NSAIDs. We recently showed that celecoxib, in contrast to other NSAIDs, did not inhibit but activate NF-κB and NF-κB-dependent gene transcription (202), suggesting that its cyclooxygenase-independent actions may also differ from those of nonselective agents. NF-κB activation caused by high concentrations of celecoxib resulted in a complete loss of its anti-inflammatory efficacy (202). It is not yet known whether this NF-κB-activating effect is shared by all COX-2-selective agents or whether it is a special feature of celecoxib.

Celecoxib was repeatedly shown to reduce colon carcinogenesis in animals and humans (203–205). Thus, it apparently possesses antitumor activity similar to that of salicylates. These effects might be due in part to the activation of NF-κB since it has been reported that activation of NF-κB in colon cancer cells causes an up-regulation of FasL and facilitation of Fas-mediated killing (74) and a sensitization to apoptosis-inducing treatments such as chemo- or radiotherapy (206). This is supported by a recent study demonstrating that aspirin activates NF-κB in colon cancer cell lines by increasing the phosphorylation and subsequent degradation of IκB, which was associated with induction of apoptosis (207). Aspirin had no effect in cells of noncolonic origin (207), suggesting that the activation of NF-κB by aspirin is cell type specific and may explain why aspirin mainly prevents colon cancer. The apparent contradiction that aspirin may both inhibit and activate NF-κB could be explained by the cell type and stimulus, since NF-κB inhibition was observed mainly in immune cells after cytokine stimulation whereas NF-κB activation occurred in colon cancer cells only when aspirin was administered alone (207). In addition, the outcome is probably influenced by concomitant effects on cellular kinase activity or other transcription factors. Thus, the ability of celecoxib to activate NF-κB may limit its usefulness in inflammatory diseases, but may be an interesting feature concerning colon cancer or Alzheimer disease, where an activation of NF-κB has been shown to reduce β-amyloid-induced neuronal apoptosis (63).

Inhibition of Akt phosphorylation

Celecoxib was recently shown to induce apoptosis in COX-2-expressing, androgen-responsive (LNCaP) and nonresponsive (PC-3) prostate cancer cells (208). In contrast to an earlier report that attributed the apoptotic activity of the COX-2-selective inhibitor NS398 in LCNaP to a down-regulation of Bcl-2 (209), celecoxib did not alter Bcl-2 levels and its effects were not reversed by overexpression of Bcl-2 (208). In that study, celecoxib inhibited the phosphorylation of protein kinase B (PKB/Akt), thereby blocking its antiapoptotic activity. The effects of celecoxib on Akt were independent of phosphatidylinositol-3-kinase activity and not reversed by okadaic acid, which is an inhibitor of protein phosphatases 1 and 2A, suggesting a direct effect on Akt kinase.

We do not know whether celecoxib also affects other pathways that have been shown to be modulated by nonselective NSAIDs, especially salicylates. NAG-1 expression (see above) was not affected by most COX-2-selective inhibitors with the exception of SC-58125, which suggests that there might be additional differences between unselective and COX-2-selective NSAIDs apart from those concerning NF-κB.

REFERENCES

1. Reddy, B. S., Rao, C. V., and Seibert, K. (1996) Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. *Cancer Res.* **56,** 4566–45669
2. Rao, C. V., Rivenson, A., Simi, B., Zang, E., Kelloff, G., Steele, V., and Reddy, B. S. (1995) Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. *Cancer Res.* **55,** 1464–1472
3. DuBois, R. N., Giardiello. F. M., and Smalley, W. E. (1996) Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. *Gastroenterol. Clin. N. Am.* **25,** 773–791
4. Mehta, J. L. (1998) Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects. *Clin. Cardiol.* **21,** 879–884
5. Mukamal, K. J., Mittleman, M. A., Maclure, M., Sherwood, J. B., Goldberg, R. J., and Muller, J. E. (1999) Recent aspirin use is associated with smaller myocardial infarct size and lower likelihood of Q-wave infarction. *Am. Heart J.* **137,** 1120–1128
6. Diener, H. C. (1999) Aspirin in the prevention of strokes. *Biomed. Pharmacother.* **53,** 309–311
7. Garcia Rodriguez, L. A., Varas, C., and Patrono, C. (2000) Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. *Epidemiology* **11,** 382–387
8. Pasinetti, G. M. (1998) Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. *J. Neurosci. Res.* **54,** 1–6
9. Flynn, B. L., and Theesen, K. A. (1999) Pharmacologic management of Alzheimer disease part III: nonsteroidal antiinflammatory drugs—emerging protective evidence? *Ann. Pharmacother.* **33,** 840–849
10. Vane, J. R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nat. New Biol.* **231,** 232–235
11. Dubois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Van De Putte, L. B., and Lipsky, P. E. (1998) Cyclooxygenase in biology and disease. *FASEB J.* **12,** 1063–1073
12. Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D., and DuBois, R. N. (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. *Cancer Res.* **58,** 362–366
13. Tsujii, M., and DuBois, R. N. (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. *Cell* **83,** 493–501

14. Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woerner, B. M., Edwards, D. A., Flickinger, A. G., Moore, R. J., and Seibert, K. (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. *Cancer Res.* **60,** 1306–1311

15. McCracken, J. D., Wechter, W. J., Liu, Y., Chase, R. L., Kantoci, D., Murray, E. D., Jr., Quiggle, D. D., and Mineyama, Y. (1996) Antiproliferative effects of the enantiomers of flurbiprofen. *J. Clin. Pharmacol.* **36,** 540–545

16. Zhang, X., Morham, S. G., Langenbach, R., and Young, D. A. (1999) Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. *J. Exp. Med.* **190,** 451–460

17. Shiff, S. J., Qiao, L., Tsai, L. L., and Rigas, B. (1995) Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. *J. Clin. Invest.* **96,** 491–503

18. Chiabrando, C., Castelli, M. G., Cozzi, E., Fanelli, R., Campoleoni, A., Balotta, C., Latini, R., and Garattini, S. (1989) Antiinflammatory action of salicylates: aspirin is not a prodrug for salicylate against rat carrageenin pleurisy. *Eur. J. Pharmacol.* **159,** 257–264

19. April, P., Abeles, M., Baraf, H., Cohen, S., Curran, N., Doucette, M., Ekholm, B., Goldlust, B., Knee, C. M., Lee, E., et al. (1990) Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis? *Semin. Arth. Rheum.* **19,** 20–28

20. Preston, S. J., Arnold, M. H., Beller, E. M., Brooks, P. M., and Buchanan, W. W. (1989) Comparative analgesic and anti-inflammatory properties of sodium salicylate and acetylsalicylic acid (aspirin) in rheumatoid arthritis. *Br. J. Clin. Pharmacol.* **27,** 607–611

21. Tegeder, I., Niederberger, E., Israr, E., Guhring, H., Brune, K., Euchenhofer, C., Grosch, S., and Geisslinger, G. (2001) Inhibition of NF-{kappa}B and AP-1 activation by R- and S-flurbiprofen. *FASEB J.* **15,** 2–4

22. Geisslinger, G., Ferreira, S. H., Menzel, S., Schlott, D., and Brune, K. (1994) Antinociceptive actions of R(−)-flurbiprofen—a non-cyclooxygenase inhibiting 2-arylpropionic acid—in rats. *Life Sci.* **54,** PL173–P177

23. Geisslinger, G., Muth-Selbach, U., Coste, O., Vetter, G., Schrodter, A., Schaible, H. G., Brune, K., and Tegeder, I. (2000) Inhibition of noxious stimulus-induced spinal prostaglandin E2 release by flurbiprofen enantiomers: a microdialysis study. *J. Neurochem.* **74,** 2094–2100

24. Wechter, W. J., Kantoci, D., Murray, Jr., E. D., Quiggle, D.D., Leipold, D. D., Gibson, K. M., and McCracken, J. D. (1997) R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. *Cancer Res.* **57,** 4316–4324

25. Wechter, W. J., Leipold, D. D., Murray, Jr., E. D., Quiggle, D., McCracken, J. D., Barrios, R. S., and Greenberg, N. M. (2000) E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. *Cancer Res.* **60,** 2203–2208

26. Goldberg, Y., Nassif, I. I., Pittas, A., Tsai, L. L., Dynlacht, B. D., Rigas, B., and Shiff, S. J. (1996) The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. *Oncogene* **12,** 893–901

27. Barnes, C. J., Cameron, I. L., Hardman, W. E., and Lee, M. (1998) Non-steroidal anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. *Br. J. Cancer* **77,** 573–580

28. Shao, J., Fujiwara, T., Kadowaki, Y., Fukazawa, T. Waku, T., Itoshima, T., Yamatsuji, T., Nishizaki, M., Roth, J. A., and Tanaka, N. (2000) Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. *Oncogene* **19,** 726–736

29. Giardina, C., Boulares, H., and Inan, M. S. (1999) NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species. *Biochim. Biophys. Acta* **1448,** 425–438

30. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., and DuBois, R. N. (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. *Cell* **93,** 705–716

31. Jones, M. K., Wang, H., Peskar, B. M., Levin, E., Itani, R. M., Sarfeh, I. J., and Tarnawski, A. S. (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. *Nat. Med.* **5,** 1418–1423

32. Hanif, R., Pittas, A., Feng, Y., Koutsos, M. I., Qiao, L., Staiano-Coico, L., Shiff, S. I., and Rigas, B. (1996) Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. *Biochem. Pharmacol.* **52,** 237–245

33. Kopp, E., and Ghosh, S. (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. *Science* **265,** 956–959

34. Pahl, H. L. (1999) Activators and target genes of Rel/NF-kappaB transcription factors. *Oncogene* **18,** 6853–6866

35. Baeuerle, P. A., and Baltimore, D. (1996) NF-kappa B: ten years after. *Cell* **87,** 13–20

36. Bayon, Y., Alonso, A., and Sanchez Crespo, M. (1999) 4-Trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor kappaB activation. *Br. J. Pharmacol.* **126,** 1359–1366

37. Cronstein, B. N., Montesinos, M. C., and Weissmann, G. (1999) Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. *Proc. Natl. Acad. Sci. USA* **96,** 6377–6381

38. De Bosscher, K., Schmitz, M. L., Vanden Berghe, W., Plaisance, S., Fiers, W., and Haegeman, G. (1997) Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. *Proc. Natl. Acad. Sci. USA* **94,** 13504–13509

39. Scheinman, R. I., Cogswell, P. C., Lofquist, A. K., and Baldwin, A. S., Jr. (1995) Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. *Science* **270,** 283–286

40. Scheinman, R. I., Gualberto, A., Jewell, C. M., Cidlowski, J. A., and Baldwin, A. S., Jr. (1995) Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. *Mol. Cell. Biol.* **15,** 943–953

41. Rescigno, M., Martino, M., Sutherland, C. L., Gold, M. R., and Ricciardi-Castagnoli, P. (1998) Dendritic cell survival and maturation are regulated by different signaling pathways. *J. Exp. Med.* **188,** 2175–2180

42. Matasic, R., Dietz, A. B., and Vuk-Pavlovic, S. (2000) Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. *Immunology* **101,** 53–60

43. Woltman, A. M., de Fijter, J. W., Kamerling, S. W., Paul, L. C., Daha, M. R., and van Kooten, C. (2000) The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. *Eur. J. Immunol.* **30,** 1807–1812

44. Shackelford, R. E., Alford, P. B., Xue, Y., Thai, S. F., Adams, D. O., and Pizzo, S. (1997) Aspirin inhibits tumor necrosis factor alpha gene expression in murine tissue macrophages. *Mol. Pharmacol.* **52,** 421–429

45. Sanchez de Miguel, L., de Frutos, T., Gonzalez-Fernandez, F., del Pozo, V., Lahoz, C., Jimenez. A., Rico, L., Garcia, R., Aceituno, E., Millas, I., Gomez, J., Farre, J., Casado, S., and Lopez-Farre, A. (1999) Aspirin inhibits inducible nitric oxide synthase expression and tumour necrosis factor-alpha release by cultured smooth muscle cells: *Eur J. Clin. Invest.* **29,** 93–99

46. Bitko, V., Velazquez, A., Yang, L., Yang, Y. C., and Barik, S. (1997) Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa B and is inhibited by sodium salicylate and aspirin. *Virology* **232,** 369–378

47. Cianferoni, A., Schroeder, J. T., Kim, J., Schmidt, J. W., Lichtenstein, L. M., Georas, S. N., and Casolaro, V. (2001) Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. *Blood* **97,** 1742–1749

48. McKenzie, A. N. (2000) Regulation of T helper type 2 cell immunity by interleukin-4 and interleukin-13. *Pharmacol. Ther.* **88,** 143–151

49. Denning, D. W. (1983) Kawasaki disease and aspirin. *Lancet* **2,** 621

50. Baum, J. (1983) Aspirin in the treatment of juvenile arthritis. *Am. J. Med.* **74,** 10–15

51. Rayet, B., and Gelinas, C. (1999) Aberrant rel/nfkb genes and activity in human cancer. *Oncogene* **18,** 6938–6947

52. Liu, Z. G., Hsu, H., Goeddel, D. V., and Karin, M. (1996) Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. *Cell* **87,** 565–576

53. Paillard, F. (1999) Induction of apoptosis with I-kappaB, the inhibitor of NF-kappaB. *Hum. Gene Ther.* **10,** 1–3

54. McDade, T. P., Perugini, R. A., Vittimberga, F. J., Jr., Carrigan, R. C., and Callery, M. P. (1999) Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells. *J. Surg. Res.* **83,** 56–61

55. Mayo, M. W., Wang, C. Y., Cogswell, P. C., Rogers-Graham, K. S., Lowe, S. W., Der, C. J., and Baldwin, A. S., Jr. (1997) Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. *Science* **278,** 1812–1815

56. Arsura, M., Mercurio, F., Oliver, A. L., Thorgeirsson, S. S., and Sonenshein, G. E. (2000) Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. *Mol. Cell. Biol.* **20,** 5381–5391

57. Ljungdahl, S., Shoshan, M. C., and Linder, S. (1997) Inhibition of the growth of 12V-ras-transformed rat fibroblasts by acetylsalicylic acid correlates with inhibition of NF-kappa B. *Anticancer Drugs* **8,** 62–66

58. Clemens, J. A., Stephenson, D. T., Yin, T., Smalstig, E. B., Panetta, J. A., and Little, S. P. (1998) Drug-induced neuroprotection from global ischemia is associated with prevention of persistent but not transient activation of nuclear factor-kappaB in rats. *Stroke* **29,** 677–682

59. Grilli, M., Pizzi, M., Memo, M., and Spano, P. (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. *Science* **274,** 1383–1385

60. Bales, K. R., Du, Y., Dodel, R. C., Yan, G. M., Hamilton-Byrd, E., and Paul, S. M. (1998) The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. *Mol. Brain Res.* **57,** 63–72

61. Barger, S. W., Horster, D., Furukawa, K., Goodman, Y., Krieglstein, J., and Mattson, M. P. (1995) Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca^{2+} accumulation. *Proc. Natl. Acad. Sci. USA* **92,** 9328–9332

62. Mattson, M. P., Goodman, Y., Luo, H., Fu, W., and Furukawa, K. (1997) Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. *J. Neurosci. Res.* **49,** 681–697

63. Kaltschmidt, B., Uherek, M., Wellmann, H., Volk, B., and Kaltschmidt, C. (1999) Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis. *Proc. Natl. Acad. Sci. USA* **96,** 9409–9414

64. Barger, S. W., and Harmon, A. D. (1997) Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. *Nature (London)* **388,** 878–881

65. Stewart, W. F., Kawas, C., Corrada, M., and Metter, E. J. (1997) Risk of Alzheimer's disease and duration of NSAID use. *Neurology* **48,** 626–632

66. Beard, C. M., Waring, S. C., O'Brien, P. C., Kurland, L. T., and Kokmen, E. (1998) Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota: 1980 through 1984. *Mayo Clin. Proc.* **73,** 951–955

67. Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) Clinical trial of indomethacin in Alzheimer's disease. *Neurology* **43,** 1609–1611

68. Scharf, S., Mander, A., Ugoni, A., Vajda, F., and Christophidis, N. (1999) A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. *Neurology* **53,** 197–201

69. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldwin, A. S. Jr. (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. *Science* **281,** 1680–1683

70. Jones, R. G., Parsons, M., Bonnard, M., Chan, V. S., Yeh, W. C., Woodgett, J. R., and Ohashi, P. S. (2000) Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. *J. Exp. Med.* **191,** 1721–1734

71. Lee, R., and Collins, T. (2001) Nuclear factor-kappaB and cell survival: IAPs call for support. *Circ. Res.* **88,** 262–264

72. Klampfer, L., Cammenga, J., Wisniewski, H. G., and Nimer, S. D. (1999) Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines. *Blood* **93,** 2386–2394

73. Kasibhatla, S., Genestier, L., and Green, D. R. (1999) Regulation of fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappaB. *J. Biol. Chem.* **274,** 987–992

74. Harwood, F. G., Kasibhatla, S., Petak, I., Vernes, R. Green, D. R., and Houghton, J. A. (2000) Regulation of FasL by NF-kappaB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells. *J. Biol. Chem.* **275,** 10023–10029

75. Kuhnel, F., Zender, L., Paul, Y., Tietze, M. K., Trautwein, C., Manns, M., and Kubicka, S. (2000) NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. *J. Biol. Chem.* **275,** 6421–6427

76. Hsu, S. C., Gavrilin, M. A., Lee, H. H., Wu, C. C., Han, S. H., and Lai, M. Z. (1999) NF-kappa B-dependent Fas ligand expression. *Eur. J. Immunol.* **29,** 2948–2956

77. Chan, H., Bartos, D. P., and Owen-Schaub, L. B. (1999) Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50–p65 recruitment. *Mol. Cell. Biol.* **19,** 2098–2108

78. Abramson, S., Korchak, H., Ludewig, R., Edelson, H., Haines, K., Levin, R. I., Herman, R., Rider, L., Kimmel, S., and Weissmann, G. (1985) Modes of action of aspirin-like drugs. *Proc. Natl. Acad. Sci. USA* **82,** 7227–7231

79. Frantz, B., and O'Neill, E. A. (1995) The effect of sodium salicylate and aspirin on NF-kappa B. *Science* **270,** 2017–2019

80. Pierce, J. W., Read, M. A., Ding, H., Luscinskas, F. W., and Collins, T. (1996) Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. *J. Immunol.* **156,** 3961–3969

81. Yin, M. J., Yamamoto, Y., and Gaynor, R. B. (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. *Nature (London)* **396,** 77–80

82. Stuhlmeier, K. M., Li, H., and Kao, J. J. (1999) Ibuprofen: new explanation for an old phenomenon. *Biochem. Pharmacol.* **57,** 313–320

83. Palayoor, S. T., Youmell, M. Y., Calderwood, S. K., Coleman, C. N., and Price, B. D. (1999) Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. *Oncogene* **18,** 7389–7394

84. Yamamoto, Y., Yin, M. J., Lin, K. M., and Gaynor, R. B. (1999) Sulindac inhibits activation of the NF-kappaB pathway. *J. Biol. Chem.* **274,** 27307–27314

85. Feinstein, D. L., Galea, E., Aquino, D. A., Li, G. C., Xu, H., and Reis, D. J. (1996) Heat shock protein 70 suppresses astroglial-inducible nitric-oxide synthase expression by decreasing NFkappaB activation. *J. Biol. Chem.* **271,** 17724–17732

86. Fujihara, S. M., and Nadler, S. G. (1999) Intranuclear targeted delivery of functional NF-kappaB by 70 kDa heat shock protein. *EMBO J.* **18,** 411–419

87. Nadler, S. G., Eversole, A. C., Tepper, M. A., and Cleaveland, J. S. (1995) Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergulin. *Ther. Drug Monit.* **17,** 700–703

88. Nadler, S. G., Tepper, M. A., Schacter, B., and Mazzucco, C. E. (1992) Interaction of the immunosuppressant deoxyspergulin with a member of the Hsp70 family of heat shock proteins. *Science* **258,** 484–486

89. Sakurada, S., Kato, T., and Okamoto, T. (1996) Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. *Int. Immunol.* **8,** 1483–1493

90. Alonso, A., Bayon, Y., Renedo, M., and Crespo, M. S. (2000) Stimulation of Fc gamma R receptors induces monocyte chemoattractant protein-1 in the human monocytic cell line THP-1 by a mechanism involving I kappa B-alpha degradation and formation of p50/p65 NF-kappa B/Rel complexes. *Int. Immunol.* **12,** 547–554

91. Lemay, S., Lebedeva, T. V., and Singh, A. K. (1999) Inhibition of cytokine gene expression by sodium salicylate in a macrophage

cell line through an NF-kappaB-independent mechanism. *Clin. Diagn. Lab. Immunol.* **6,** 567–572

92. Gautam, S. C., Pindolia, K. R., Noth, C. J., Janakiraman, N., Xu, Y. X., and Chapman, R. A. (1995) Chemokine gene expression in bone marrow stromal cells: downregulation with sodium salicylate. *Blood* **86,** 2541–2550

93. Kleinert, H., Euchenhofer, C., Ihrig-Biedert, I., and Forster-mann, U. (1996) Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-kappa B. *Mol. Pharmacol.* **49,** 15–21

94. Kleinert, H., Wallerath, T., Fritz, G., Ihrig-Biedert, I., Rodriguez-Pascual, G., Geller, D. A., and Forstermann, U. (1998) Cytokine induction of NO synthase II in human DLD-1 cells: roles of the JAK-STAT, AP-1 and NF-kappaB-signaling pathways. *Br. J. Pharmacol.* **125,** 193–201

95. Dong, Z., Huang, C., Brown, R. E., and Ma, W. Y. (1997) Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. *J. Biol. Chem.* **272,** 9962–9970

96. Yoshizaki, T., Sato, H., Furukawa, M., and Pagano, J. S. (1998) The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. *Proc. Natl. Acad. Sci. USA* **95,** 3621–3626

97. Murono, S., Yoshizaki, T., Sato, H., Takeshita, H., Furukawa, M., and Pagano, J. S. (2000) Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. *Cancer Res.* **60,** 2555–2561

98. Keyszer, G. M., Heer, A. H., Kriegsmann, J., Geiler, T., Tra-bandt, A., Keysser, M., Gay, R. E., and Gay, S. (1995) Comparative analysis of cathepsin L, cathepsin D, and collagenase messenger RNA expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis, by in situ hybridization. *Arth. Rheum.* **38,** 976–984

99. Firestein, G. S., Paine, M. M., and Littman, B. H. (1991) Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium. Quantitative analysis and effect of intraarticular corticosteroids. *Arth. Rheum.* **34,** 1094–1105

100. Han, Z., Boyle, D. L., Manning, A. M., and Firestein, G. S. (1998) AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. *Autoimmunity* **28,** 197–208

101. Yamazaki, R., Kawai, S., Mizushima, Y., Matsuzaki, T., Hashi-moto, S., Yokokura, T., and Ito, A. (2000) A major metabolite of aceclofenac, 4′-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-strome-lysin-1/proMMP-3 by human rheumatoid synovial cells. *Inflamm. Res.* **49,** 133–138

102. Huang, C., Ma, W. Y., Hanenberger, D., Cleary, M. P., Bowden, G. T., and Dong, Z. (1997) Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. *J. Biol. Chem.* **272,** 26325–26331

103. Pillinger, M. H., Capodici, C., Rosenthal, P., Kheterpal, N., Hanft, S., Philips, M. R., and Weissmann, G. (1998) Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. *Proc. Natl. Acad. Sci. USA* **95,** 14540–14545

104. Schwenger, P., Skolnik, E. Y., and Vilcek, J. (1996) Inhibition of tumor necrosis factor-induced p42/p44 mitogen-activated protein kinase activation by sodium salicylate. *J. Biol. Chem.* **271,** 8089–8094

105. Schwenger, P., Alpert, D., Skolnik, E. Y., and Vilcek, J. (1998) Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation. *Mol. Cell. Biol.* **18,** 78–84

106. Schwenger, P., Bellosta, P., Vietor, I., Basilico, C., Skolnik, E. Y., and Vilcek, J. (1997) Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. *Proc. Natl. Acad. Sci. USA* **94,** 2869–2873

107. Schwenger, P., Alpert, E., Skolnik, E. Y., and Vilcek, J. (1999) Cell-type-specific activation of c-Jun N-terminal kinase by salicylates. *J. Cell. Physiol.* **179,** 109–114

108. Stevenson, M. A., Zhao, M. J., Asea, A., Coleman, C. N., and Calderwood, S. K. (1999) Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcrip-

109. Chen, L. C., Kepka-Lenhart, D., Wright, T. M., and Morris, S. M., Jr. (1999) Salicylate-enhanced activation of transcription factors induced by interferon-gamma. *Biochem. J.* **342,** 503–507

110. Chen, B., He, L., Savell, V. H., Jenkins, J. J., and Parham, D. M. (2000) Inhibition of the interferon-gamma/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region. *Cancer Res.* **60,** 3290–3298

111. Coccia, E M., Del Russo, N., Stellacci, E., Testa, U., Marziali, G., and Battistini, A. (1999) STAT1 activation during monocyte to macrophage maturation: role of adhesion molecules. *Int. Immunol.* **11,** 1075–1083

112. Ohmori, Y., Schreiber, R. D., and Hamilton, T. A. (1997) Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. *J. Biol. Chem.* **272,** 14899–14907

113. Ala-aho, R., Johansson, N., Grenman, R., Fusenig, N. E., Lopez-Otin, C., and Kahari, V. M. (2000) Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1. *Oncogene* **19,** 248–257

114. Levy, D. E., and Gilliland, D. G. (2000) Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. *Oncogene* **19,** 2505–2510

115. Baek, S. J., Kim, K. S., Nixon, J. B., Wilson, L., C., and Eling, T. E. (2001) Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. *Mol. Pharmacol.* **59,** 901–908

116. Bootcov, M. R., Bauskin, A. R., Valenzuela, S. M., Moore, A. G., Bansal, M., He, X. Y., Zhang, H. P., Donnellan, M., Mahler, S., Pryor, K., Walsh, B. J., Nicholson, R. C., Fairlie, W. D., Por, S. B., Robbins, J. M., and Breit, S. N. (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. *Proc. Natl. Acad. Sci. USA* **94,** 11514–11519

117. Lawton, L. N., Bonaldo, M. F., Jelenc, P. C., Qiu, L., Baumes, S. A., Marcelino, R. A., de Jesus, G. M., Wellington, S., Knowles, J. A., Warburton, D., Brown, S., and Soares, M. B. (1997) Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. *Gene* **203,** 17–26

118. Li, P. X., Wong, J., Ayed, A., Ngo, D., Brade, A. M., Arrowsmith, C., Austin, R. C., and Klamut, H. J. (2000) Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. *J. Biol. Chem.* **275,** 20127–20135

119. Tan, M., Wang, Y., Guan, K., and Sun, Y. (2000) PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. *Proc. Natl. Acad. Sci. USA* **97,** 109–114

120. Law, B. K., Waltner-Law, M. E., Entingh, A. J., Chytil, A., Aakre, M. C., Norgaard, P., and Moses, H. L. (2000) Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. *J. Biol. Chem.* **275,** 38261–38267

121. Hashemolhosseini, S., Nagamine, Y., Morley, S. J., Desrivieres, S., Mercep, L., and Ferrari, S. (1998) Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. *J. Biol. Chem.* **273,** 14424–14429

122. Perugini, R. A., McDade, T. P., Vittimberga, F. J., Jr., Duffy, A. J., and Callery, M. P. (2000) Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines. *J. Gastrointest. Surg.* **4,** 24–32

123. Sherr, C. J. (1993) Mammalian G1 cyclins. *Cell* **73,** 1059–1065

124. Matsushime, H., Quelle, D. E., Shurtleff, S. A., Shibuya, M., Sherr, C. J., and Kato, J. Y. (1994) D-type cyclin-dependent kinase activity in mammalian cells. *Mol. Cell. Biol.* **14,** 2066–2076

125. Meyerson, M., and Harlow, E. (1994) Identification of G1 kinase activity for cdk6, a novel cyclin D partner. *Mol. Cell. Biol.* **14,** 2077–2086

126. Koff, A., Giordano, A., Desai, D., Yamashita, K., Harper, J. W., Elledge, S., Nishimoto, T., Morgan, D. O., Franza, B. R., and Roberts, J. M. (1992) Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. *Science* **257,** 1689–1694

127. Dulic, V., Lees, E., and Reed, S. I. (1992) Association of human cyclin E with a periodic G1-S phase protein kinase. *Science* **257,** 1958–1961

128. Ohtsubo, M., and Roberts, J. M. (1993) Cyclin-dependent regulation of G1 in mammalian fibroblasts. *Science* **259,** 1908–1912

129. Resnitzky, D., Gossen, M., Bujard, H., and Reed, S. I. (1994) Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. *Mol. Cell. Biol.* **14,** 1669–1679

130. Fang, F., and Newport, J. W. (1991) Evidence that the G1-S and G2-M transitions are controlled by different cdc2 proteins in higher eukaryotes. *Cell* **66,** 731–742

131. Riabowol, K., Draetta, G., Brizuela, L., Vandre, D., and Beach, D. (1989) The cdc2 kinase is a nuclear protein that is essential for mitosis in mammalian cells. *Cell* **57,** 393–401

132. van den Heuvel, S., and Harlow, E. (1993) Distinct roles for cyclin-dependent kinases in cell cycle control. *Science* **262,** 2050–2054

133. Pines, J., and Hunter, T. (1989) Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. *Cell* **58,** 833–846

134. Weinberg, R. A. (1995) The retinoblastoma protein and cell cycle control. *Cell* **81,** 323–330

135. Nevins, J. R. (1992) E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. *Science* **258,** 424–429

136. Marra, D. E., Simoncini, T., and Liao, J. K. (2000) Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1). *Circulation* **102,** 2124–2130

137. Bellas, R. E., Lee, J. S., and Sonenshein, G. E. (1995) Expression of a constitutive NF-kappa B-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. *J. Clin. Invest.* **96,** 2521–2527

138. Jurivich, D. A., Sistonen, L., Kroes, R. A., and Morimoto, R. I. (1992) Effect of sodium salicylate on the human heat shock response. *Science* **255,** 1243–1245

139. Jurivich, D. A., Pachetti, C., Qiu, L., and Welk, J. F. (1995) Salicylate triggers heat shock factor differently than heat. *J. Biol. Chem.* **270,** 24489–24495

140. Housby, J. N., Cahill, C. M., Chu, B., Prevelige, R., Bickford, K., Stevenson, M. A., and Calderwood, S. K. (1999) Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. *Cytokine* **11,** 347–358

141. Amberger, A., Hala, M. Saurwein-Teissl, M., Metzler, B., Grubeck-Loebenstein, B., Xu, Q., and Wick, G. (1999) Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins. *Mol. Med.* **5,** 117–128

142. Wang, X., Asea, A., Xie, Y., Kabingu, E., Stevenson, M. A., and Calderwood, S. K. (2000) RSK2 represses HSF1 activation during heat shock. *Cell Stress Chaperones* **5,** 432–437

143. Weber, C., Erl, W., Pietsch, A., and Weber, P. C. (1995) Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. *Circulation* **91,** 1914–1917

144. Oeth, P., and Mackman, N. (1995) Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells. *Blood* **86,** 4144–4152

145. Williams, D. H., Jeffery, L. J., and Murray, E. J. (1992) Aurothioglucose inhibits induced NF-κB and AP-1 activity by acting as an IL-1 functional antagonist. *Biochim. Biophys. Acta* **1180,** 9–14

146. Schoonjans, K., Staels, B., and Auwerx, J. (1996) The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. *Biochim. Biophys. Acta* **1302,** 93–109

147. Willson, T. M., Brown, P. J., Sternbach, D. D., and Henke, B. R. (2000) The PPARs: from orphan receptors to drug discovery. *J. Med. Chem.* **43,** 527–550

148. Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., and Evans, R. M. (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. *Proc. Natl. Acad. Sci. USA* **91,** 7355–7359

149. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). *J. Biol. Chem.* **270,** 12953–12956

150. Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., and Kliewer, S. A. (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. *J. Biol. Chem.* **272,** 3406–3410

151. Knight, D. M., Chapman, A. B., Navre, M., Drinkwater, L., Bruno, J. J., and Ringold, G. M. (1987) Requirements for triggering of adipocyte differentiation by glucocorticoids and indomethacin. *Mol. Endocrinol.* **1,** 36–43

152. Gimble, J. M., Youkhana, K., Hua, X., Bass, H., Medina, K., Sullivan, M., Greenberger, J., and Wang, C. S. (1992) Adipogenesis in a myeloid supporting bone marrow stromal cell line. *J. Cell. Biochem.* **50,** 73–82

153. Ye, H., and Serrero, G. (1998) Stimulation of adipose differentiation related protein (ADRP) expression by ibuprofen and indomethacin in adipocyte precursors and in adipocytes. *Biochem. J.* **330,** 803–809

154. Slieker, L. J., Sloop, K. W., and Surface, P. L. (1998) Differentiation method-dependent expression of leptin in adipocyte cell lines. *Biochem. Biophys. Res. Commun.* **251,** 225–229

155. Yu, K., Bayona, W., Kallen, C. B., Harding, H. P., Ravera, C. P., McMahon, G., Brown, M., and Lazar, M. A. (1995) Differential activation of peroxisome proliferator-activated receptors by eicosanoids. *J. Biol. Chem.* **270,** 23975–23983

156. Keelan, J. A., Sato, T. A., Marvin, K. W., Lander, J., Gilmour, R. S., and Mitchell, M. D. (1999) 15-Deoxy-delta(12,14)-prostaglandin J$_2$, a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. *Biochem. Biophys. Res. Commun.* **262,** 579–585

157. Sinha, D., Addya, S., Murer, E., and Boden, G. (1999) 15-Deoxy-delta(12,14) prostaglandin J2: a putative endogenous promoter of adipogenesis suppresses the ob gene. *Metabolism* **48,** 786–791

158. Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., and Lehmann, J. M. (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. *Cell* **83,** 813–819

159. Urade, Y., Ujihara, M., Horiguchi, Y., Ikai, K., and Hayaishi, O. (1989) The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. *J. Immunol.* **143,** 2982–2989

160. Lewis, R. A., Soter, N. A., Diamond, P. T., Austen, K. F., Oates, J. A., and Roberts, L. J., 2nd (1982) Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. *J. Immunol.* **129,** 1627–1631

161. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. *Nature (London)* **391,** 79–82

162. Sugiyama, H., Nonaka, T., Kishimoto, T., Komoriya, K., Tsuji, K., and Nakahata, T. (2000) Peroxisome proliferator-activated receptors are expressed in mouse bone marrow-derived mast cells. *FEBS Lett.* **467,** 259–262

163. Clark, R. B., Bishop-Bailey, D., Estrada-Hernandez, T., Hla, T., Puddington, L., and Padula, S. J. (2000) The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. *J. Immunol.* **164,** 1364–1371

164. Huang, J. T., Welch, J. S., Ricote, M., Binder, C. J., Willson, T. M., Kelly, C., Witztum, J. L., Funk, C. D., Conrad, D., and Glass, C. K. (1999) Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. *Nature (London)* **400,** 378–382

165. Jiang, C., Ting, A. T., and Seed, B. (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. *Nature (London)* **391,** 82–86

166. Heneka, M. T., Feinstein, D. L., Galea, E., Gleichmann, M., Wullner, U., and Klockgether, T. (1999) Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. *J. Neuroimmunol.* **100,** 156–168

167. Chinetti, G., Griglio, S., Antonucci, M., Torra, I. P., Delerive, P., Majd, Z., Fruchart, J. C., Chapman, J., Najib, J., and Staels, B. (1998) Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. *J. Biol. Chem.* **273,** 25573–25580

168. Kawahito, Y., Kondo, M., Tsubouchi, Y., Hashiramoto, A., Bishop-Bailey, D., Inoue, K., Kohno, M., Yamada, R., Hla, T., and Sano, H. (2000) 15-Deoxy-delta(12,14)-PGJ$_2$ induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. *J. Clin. Invest.* **106,** 189–197

169. Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers, J., Paul-Clark, M. J., and Willoughby, D. A. (1999) Inducible cyclooxygenase may have anti-inflammatory properties. *Nat. Med.* **5,** 698–701

170. Sarraf, P., Mueller, E., Jones, D., King, R. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., and Spiegelman, B. M. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARgamma. *Nat. Med.* **4,** 1046–1052

171. Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., and Spiegelman, B. M. (1998) Terminal differentiation of human breast cancer through PPAR gamma. *Mol. Cell* **1,** 465–470

172. Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., Said, J. W., Holden, S., Miyoshi, I., and Koeffler, H. P. (1998) Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. *Cancer Res.* **58,** 3344–3352

173. Clay, C. E., Namen, A. M., Atsumi, G., Willingham, M. C., High, K. P., Kute, T. E., Trimboli, A. J., Fonteh, A. N., Dawson, P. A., and Chilton, F. H. (1999) Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. *Carcinogenesis* **20,** 1905–1911

174. Sarraf, P., Mueller, E., Smith, W. M., Wright, H. M., Kum, J. B., Aaltonen, L. A., de la Chapelle, A., Spiegelman, B. M., and Eng, C. (1999) Loss-of-function mutations in PPAR gamma associated with human colon cancer. *Mol. Cell* **3,** 799–804

175. Djordjevic, B., Lange, C. S., Schwartz, M. S., and Rotman, M. (1998) Clonogenic inactivation of colon cancer-derived cells treated with 5-fluorouracil and indomethacin in hybrid spheroids. *Acta Oncol.* **37,** 735–739

176. Lim, H., Gupta, R. A., Ma, W. G., Paria, B. C., Moller, D. E., Morrow, J. D., Dubois, R. N., Trzaskos, J. M., and Dey, S. K. (1999) Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. *Genes Dev.* **13,** 1561–1574

177. Papkoff, J., Rubinfeld, B., Schryver, B., and Polakis, P. (1996) Wnt-1 regulates free pools of catenins and stabilizes APC-catenin complexes. *Mol. Cell. Biol.* **16,** 2128–2134

178. He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. AT., Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1998) Identification of c-MYC as a target of the APC pathway. *Science* **281,** 1509–1512

179. Tetsu, O., and McCormick, F. (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature (London)* **398,** 422–426

180. He, T. C., Chan, T. A., Vogelstein, B., and Kinzler, K. W. (1999) PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. *Cell* **99,** 335–345

181. Koh, T. J., Bulitta, C. J., Fleming, J. V., Dockray, G. J., Varro, A., and Wang, T. C. (2000) Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. *J. Clin. Invest.* **106,** 533–539

182. Hart, M. J., de los Santos, R., Albert, I. N., Rubinfeld, B., and Polakis, P. (1998) Downregulation of beta-catenin by human axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. *Curr. Biol.* **8,** 573–581

183. Rubinfeld, B., Souza, B., Albert, I., Muller, O., Chamberlain, S. H., Masiarz, F. R., Munemitsu, S., and Polakis, P. (1993) Association of the APC gene product with beta-catenin. *Science* **262,** 1731–1734

184. Munemitsu, S., Albert, I., Souza, B., Rubinfeld, B., and Polakis, P. (1995) Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. *Proc. Natl. Acad. Sci. USA* **92,** 3046–3050

185. Su, L. K., Vogelstein, B., and Kinzler, K. W. (1993) Association of the APC tumor suppressor protein with catenins. *Science* **262,** 1734–1737

186. Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., and Polakis, P. (1997) Stabilization of beta-catenin by genetic defects in melanoma cell lines. *Science* **275,** 1790–1792

187. Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and Kinzler, K. W. (1997) Activation of beta-catenin-TCF signaling in colon cancer by mutations in beta-catenin or APC. *Science* **275,** 1787–1790

188. Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1996) Apoptosis and APC in colorectal tumorigenesis. *Proc. Natl. Acad. Sci. USA* **93,** 7950–7954

189. Kishimoto, Y., Takata, N., Jinnai, T., Morisawa, T., Shiota, G., Kawasaki, H., and Hasegawa, J. (2000) Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane. *Gut* **47,** 812–819

190. Mahmoud, N. N., Dannenberg, A. J., Mestre, J., Bilinski, R. T., Churchill, M. R., Martucci, C., Newmark, H., and Bertagnolli, M. M. (1998) Aspirin prevents tumors in a murine model of familial adenomatous polyposis. *Surgery* **124,** 225–231

191. Smith, M. L., Hawcroft, G., and Hull, M. A. (2000) The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. *Eur. J. Cancer* **36,** 664–674

192. Gupta, R. A., Tan, J., Krause, W. F., Geraci, M. W., Willson, T. M., Dey, S. K., and DuBois, R. N. (2000) Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. *Proc. Natl. Acad. Sci. USA* **97,** 13275–13280

193. Piazza, G. A., Alberts, D. S., Hixson, L. J., Paranka, N. S., Li, H., Finn, T., Bogert, C., Guillen, J. M., Brendel, K., Gross, P. H., Sperl, G., Ritchie, J., Burt, R. W., Ellsworth, L., Ahnen, D. J., and Pamukcu. R. (1997) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. *Cancer Res.* **57,** 2909–2915

194. Kang, H. J., Song, M. J., Choung, S. Y., Kim, S. J., and Le, M. O. (2000) Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells. *Biol. Pharm. Bull.* **23,** 815–819

195. Milbrandt, J. (1988) Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene. *Neuron* **1,** 183–188

196. Hazel, T. G., Nathans, D., and Lau, L. F. (1988) A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily. *Proc. Natl. Acad. Sci. USA* **85,** 8444–8448

197. Wilson, T. E., Fahrner, T. J., Johnston, M., and Milbrandt, J. (1991) Identification of the DNA binding site for NGFI-B by genetic selection in yeast. *Science* **252,** 1296–1300

198. Kuang, A. A., Cado, D., and Winoto, A. (1999) Nur77 transcription activity correlates with its apoptotic function in vivo. *Eur. J. Immunol.* **29,** 3722–3728

199. Youn, H. D., Sun, L., Prywes, R., and Liu, J. O. (1999) Apoptosis of T cells mediated by Ca^{2+}-induced release of the transcription factor MEF2. *Science* **286,** 790–793

200. van den Brink, M. R., Kapeller, R., Pratt, J. C., Chang, J. H., and Burakoff, S. J. (1999) The extracellular signal-regulated kinase pathway is required for activation-induced cell death of T cells. *J. Biol. Chem.* **274,** 11178–11185

201. Li, H., Kolluri, S. K., Gu, J., Dawson, M. I., Cao, X., Hobbs, P. D., Lin, B., Chen, G, Lu, J., Lin, F., Xie, Z., Fontana, J. A., Reed, J. C., and Zhang, X. (2000) Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. *Science* **289,** 1159–1164

202. Niederberger, E., Tegeder, I., Vetter, G., Schmidtko, A., Schmidt, H., Bräutigam, L., Euchenhofer, C., Grösch, S., and Geisslinger, G. (2001) Celecoxib loses its anti-inflammatory efficacy at high doses by activation of NF-κB. *FASEB J.* **15,** 1622–1624

203. Reddy, S., Hirose, Y., Lubet, R., Steele, V., Kelloff, G., Paulson, S., Seibert, K., and Rao, C. V. (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. *Cancer Res.* **60,** 293–297

204. Jacoby, R. F., Seibert, K., Cole, C. E., Kelloff, G., and Lubet, R. A. (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. *Cancer Res.* **60,** 5040–5044

205. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., and Levin, B. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N. Engl. J. Med.* **342,** 1946–1952

206. Han, S.Y., Choung, S. Y., Paik, I. S., Kang, H. J., Choi, Y. H., Kim, S. J., and Lee, M. O. (2000) Activation of NF-kappaB determines the sensitivity of human colon cancer cells to TNFalpha-induced apoptosis. *Biol. Pharm. Bull.* **23,** 420–426

207. Stark, L. A., Din, F. V., Zwacka, R. M., and Dunlop, M. G. (2001) Aspirin-induced activation of the NF-κB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. *FASEB J.* **15,** 1273–1275

208. Hsu, A. L., Ching, T. T., Wang, D. S., Song, X., Rangnekar, V. M., and Chen, C. S. (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. *J. Biol. Chem.* **275,** 11397–11403

209. Liu, X. H., Yao, S., Kirschenbaum, A., and Levine, A. C. (1998) NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. *Cancer Res.* **58,** 4245–4249

210. Neupert, W., Brugger, R., Euchenhofer, C., Brune, K., and Geisslinger, G. (1997) Effects of ibuprofen enantiomers and its coenzyme A thioesters on human prostaglandin endoperoxide synthases. *Br. J. Pharmacol.* **122,** 487–492

211. Patrignani, P., Panara, M. R., Greco, A., Fusco, O., Natoli, C., Iacobelli, S., Cipollone, F., Ganci, A., Creminon, C., Maclouf, J., et al. (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prosta-glandin endoperoxide synthases. *J. Pharmacol. Exp. Ther.* **271,** 1705–1712

212. Riendeau, D., Percival, M. D., Brideau, C., Charleson, S., Dube, D., Ethier, D., Falgueyret, J. P., Friesen, R. W., Gordon, R., Greig, G., Guay, J., Mancini, J., Ouellet, M., Wong, E., Xu, L., Boyce, S., Visco, D., Girard, Y., Prasit, P., Zamboni, R., Rodger, I. W., Gresser, M., Ford-Hutchinson, A. W., Young, R. N., and Chan, C. C. (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. *J. Pharmacol. Exp. Ther.* **296,** 558–566

213. Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., and Vane, J. R. (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. *Proc. Natl. Acad. Sci. USA* **96,** 7563–7568

214. Young, J. M., Panah, S., Satchawatcharaphong, C., and Cheung, P. S. (1996) Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. *Inflamm. Res.* **45,** 246–253

215. Giuliano, F., and Warner, T. D. (1999) Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. *Br. J. Pharmacol.* **126,** 1824–1830

216. Tobetto, K., Yamamoto, Y., Kataoka, M., Ando, T., Sugimoto, K., and Himeno, M. (1997) The effects of a newly developed nonsteroidal anti-inflammatory drug (M-5011) on arachidonic acid metabolism in rheumatoid synovial fibroblasts. *Jpn. J. Pharmacol.* **75,** 371–379

217. Kawai, S., Nishida, S., Kato, M., Furumaya, Y., Okamoto, R., Koshino, T., and Mizushima, Y. (1998) Comparison of cyclo-oxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. *Eur. J. Pharmacol.* **347,** 87–94

218. Wong, E., DeLuca, C., Boily, C., Charleson, S., Cromlish, W., Denis, D., Kargman, S., Kennedy, B. P., Ouellet, M., Skorey, K., O'Neill, G. P., Vickers, P. J., and Riendeau, D. (1997) Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells. *Inflamm. Res.* **46,** 51–59